Welcome to our dedicated page for 22Nd Century news (Ticker: XXII), a resource for investors and traders seeking the latest updates and insights on 22Nd Century stock.
22nd Century Group (NASDAQ: XXII) pioneers plant-based solutions for tobacco harm reduction through advanced biotechnology. This news hub provides investors and stakeholders with essential updates on regulatory milestones, product innovations, and operational developments central to the company's mission of reducing nicotine addiction.
Access authoritative coverage of FDA communications, VLN product advancements, and manufacturing capacity updates. Our curated collection includes earnings reports, patent filings, and scientific research collaborations that demonstrate 22nd Century's leadership in developing reduced-nicotine tobacco products.
Key updates feature the company's Modified Risk Tobacco Product authorization, progress in international market expansion, and innovations in nicotine biosynthesis control. Regular updates ensure informed tracking of this biotechnology firm's unique position at the intersection of public health and commercial tobacco production.
Bookmark this page for streamlined access to verified corporate announcements and analysis-free reporting on 22nd Century's progress in redefining tobacco consumption through science-driven solutions.
22nd Century Group, Inc. (NYSE American: XXII) has announced its participation in three investor conferences throughout March 2021. The events include the DA Davidson 4th Annual Consumer Growth Conference on March 11, the 33rd Annual Roth Conference from March 15-17, and the Investor Summit Virtual Conference from March 23-25. Investors can request one-on-one meetings with the management team via conference hosts. The company focuses on tobacco harm reduction and hemp/cannabis research, emphasizing reduced nicotine content tobacco products.
22nd Century Group, Inc. (NYSE American: XXII) announced it received net proceeds of $8.1 million from warrants exercised in February and March 2021, enhancing its balance sheet. The company expects an additional $3.7 million if remaining warrants are exercised. CEO James A. Mish stated that the capital will support operations, strategy, and growth initiatives across tobacco and hemp/cannabis sectors. The funds will aid in acquiring Modified Risk Tobacco Products (MRTP) authorization and support research in hemp/cannabis.
22nd Century Group, Inc. (XXII) has secured an exclusive agreement with CannaMetrix, LLC to utilize their proprietary CannaMetrix EC50Array™ technology. This partnership aims to expedite the commercialization of innovative hemp/cannabis plant lines, reducing development time from over ten years to just two. The company has now established four out of five key partnerships needed for the cannabinoid value chain, focusing on plant profiling, biotechnology, cultivation, and extraction. This move aligns with its strategy to advance the hemp/cannabis industry significantly.
22nd Century Group (NYSE American: XXII) will host a live webcast on March 11, 2020, at 8:00 a.m. EST to discuss its fourth quarter and full-year 2020 results. The company will issue its results at 7:00 a.m. the same day. CEO James A. Mish and other executives will provide insights on 2020 performance, future milestones, and market opportunities in the $800 billion tobacco and hemp/cannabis sectors. An interactive Q&A will follow the presentation. Access to the webcast is available on the company’s investor relations page.
22nd Century Group is focused on tobacco harm reduction and hemp/cannabis research. The company reported a 343% stock increase to $3.82 as of February 23, 2021, highlighting its MRTP application for VLN® reduced nicotine cigarettes, which if approved, could position it as the only company with a MRTP designation for combustible cigarettes. The company is also advancing its cannabis strategy by developing new hemp varieties through molecular breeding technology, capitalizing on a projected $39.1 billion North American cannabis market by 2025.
22nd Century Group (NYSE American: XXII) announced a breakthrough in plant biotechnology allowing rapid identification of valuable traits in hemp/cannabis. Collaborating with KeyGene, the new platform accelerates development time and enhances breeding techniques, aiming for exponential revenue growth by licensing to partners. The platform can identify genetic markers with over 99.6% accuracy, targeting therapeutic cannabinoids like CBD. The company's strategy shift focuses on upstream segments of the cannabinoid value chain.
22nd Century Group, Inc. (NYSE American: XXII) announced its headquarters relocation to the Larkinville District in Buffalo, NY. The move, set for March 2021, aims to enhance organizational efficiency and talent retention. The company is also awaiting FDA authorization for its Modified Risk Tobacco application for VLN® cigarettes, which contain 95% less nicotine than regular cigarettes. The anticipated growth in hemp/cannabis markets and a new franchise will require the expanded headquarters, indicating a potentially pivotal year for the company.
22nd Century Group advocates for FDA regulation of nicotine levels in cigarettes to reduce addiction and save lives. CEO James A. Mish emphasizes that lowering nicotine can lead to over 8 million fewer deaths by century’s end. The proposal aligns with the FDA's prior plans to combat smoking-related diseases, which result in over 480,000 deaths annually in the U.S., costing $300 billion in healthcare. The company urges Congress to support this vital public health initiative.
22nd Century Group (XXII) announced a significant expansion of its growing program for VLN® reduced nicotine tobacco for the 2021 crop year. This increase aligns with favorable sales projections and supports the expected launch of VLN® cigarettes, which contain 95% less nicotine than conventional brands. The company is awaiting the FDA's authorization of its Modified Risk Tobacco Product application. The new planting will create income for American family farmers and aims to capture a share of the U.S. tobacco market, potentially leading to substantial revenue growth.
22nd Century Group (NYSE American: XXII) announces the granting of a new U.S. patent that enables precise control over cannabinoid and terpene production in hemp/cannabis plants. This patent allows the company to genetically modify plants to optimize therapeutic qualities, reducing development time from 10-20 years to just 4-5 years. The technology is expected to increase cannabinoid yields and create tailored plant profiles for various applications, enhancing the company's competitive edge in the growing $100 billion hemp/cannabis market.
FAQ
What is the current stock price of 22Nd Century (XXII)?
What is the market cap of 22Nd Century (XXII)?
